MBM-17S (20 mg/kg; i.p.; twice a day for 21 days) exhibits good antitumor activity and a well-tolerated dose schedule[1].
MBM-17S (1.0 mg/kg; i.v.) treatment shows CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively[1].
| Animal Model: | Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts)[1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; twice a day for 21 days |
| Result: | Tmor growth was significantly suppressed.
|
| Animal Model: | Male Sprague Dawley (SD) rats[1] |
| Dosage: | 1.0 mg/kg |
| Administration: | IV injection (Pharmacokinetic Analysis) |
| Result: | The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively.
|
